Article Information
- Received April 11, 2011
- Revision received July 9, 2011
- Accepted July 12, 2011
- First published September 7, 2011.
- Version of record published September 7, 2011.
Author Information
- Anca Alexandru1,
- Wolfgang Jagla1,
- Sigrid Graubner1,
- Andreas Becker1,
- Christoph Bäuscher1,
- Stephanie Kohlmann1,
- Reinhard Sedlmeier1,
- Kerstin A. Raber2,
- Holger Cynis3,
- Raik Rönicke4,
- Klaus G. Reymann4,5,
- Elisabeth Petrasch-Parwez6,
- Maike Hartlage-Rübsamen7,
- Alexander Waniek7,
- Steffen Rossner7,
- Stephan Schilling3,
- Alexander P. Osmand8,
- Hans-Ulrich Demuth1,3, and
- Stephan von Hörsten2
- 1Ingenium Pharmaceuticals, 82152 Martinsried, Germany,
- 2Experimental Therapy, Friedrich Alexander University Erlangen Nürnberg, 91054 Erlangen, Germany,
- 3Probiodrug, 06120 Halle/Saale, Germany,
- 4German Center of Neurodegenerative Diseases, 39120 Magdeburg, Germany,
- 5Leibniz Institute for Neurobiology, 39118 Magdeburg, Germany,
- 6Neuroanatomy and Molecular Brain Research, Ruhr University Bochum, 44801 Bochum, Germany,
- 7Paul Flechsig Institute for Brain Research, University of Leipzig, 04109 Leipzig, Germany, and
- 8Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, Tennessee 37920
Author contributions
Author contributions: S.G., S.S., and H.-U.D. designed research; A.A., W.J., C.B., S.K., R.S., K.A.R., H.C., R.R., E.P.-P., M.H.-R., A.W., S.R., S.S., and A.P.O. performed research; A.P.O. contributed unpublished reagents/analytic tools; A.A., W.J., S.G., A.B., C.B., S.K., R.S., K.A.R., H.C., R.R., K.G.R., E.P.-P., M.H.-R., A.W., S.R., S.S., A.P.O., H.-U.D., and S.v.H. analyzed data; A.A. and S.v.H. wrote the paper.
Disclosures
- Received April 11, 2011.
- Revision received July 9, 2011.
- Accepted July 12, 2011.
This work was supported by the German Council of Industrial Research Support (AIF) Grant KA0318901MD6 (to H.-U.D.). We are grateful to Mira Kellner, Sylvia Garke-Mayerthaler, Alexandra Graupner, Andrea Koppius, Kerstin Loske, Hans-Werner Habbes, Marlen Löbbecke-Schumacher, Eike Scheel, Katrin Böhm, and Carsten Jäger for their valuable technical assistance and to Robert C. Switzer III for critical discussion.
A.A., W.J., S.G., C.B., S.K., A.B., and R.S. are employees of Ingenium Pharmaceuticals. H.C. and S.S. are employees of Probiodrug. H.-U.D. serves as Chief Scientific Officer of Probiodrug and as Managing Director of Ingenium Pharmaceuticals. S.v.H. is consultant to the Probiodrug and Ingenium Group.
- Correspondence should be addressed to either of the following: Stephan von Hörsten, Department of Experimental Therapy, Friedrich Alexander University Erlangen Nürnberg, Palmsanlage 5, 91054 Erlangen, Germany, stephan.v.hoersten{at}ze.uni-erlangen.de; or Hans-Ulrich Demuth, Probiodrug, Biocenter, Weinbergweg 22, 06120 Halle (Saale), Germany, hans-ulrich.demuth{at}probiodrug.de
Online Impact